Scholars Central

ArticlePublished 2008

Erlotinib-Induced Skin Rash. Pathogenesis, Clinical Significance and Management in Pancreatic Cancer Patients

Authors: Kostas Syrigos, Muhammad Wasif Saif, Irene Merikas, Sotirios Tsimboukis

Journal of the Pancreas

Volume 9 · Issue 3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the most common side effects, rash, is possibly linked to overall and progression-free survival and may sere as a potential surrogate marker. Nevertheless, erlotinib-induced rash is cause of negative impact on patients' quality of life and often can trigger discontinuation of treatment. Adequate and timely management of rash depending on the grade of rash is important for therapy continuation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Kostas Syrigos”
  • BylineArticles whose byline prints “Muhammad Wasif Saif”
  • BylineArticles whose byline prints “Irene Merikas”
  • BylineArticles whose byline prints “Sotirios Tsimboukis”